Supplementary data: Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study

These are peer-reviewed supplementary materials for the article 'Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study' published in the Journal of Comparative Effectiveness Research.Supplementary cohort definitions (json)Supplementary concept sets expressionsAim: Finerenone is safe and efficacious for treating patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D). Evidence on the use of finerenone in clinical practice is lacking. Objective: To describe demographic and clinical characteristics of early adopters of finerenone in the United States, according to sodium-glucose cotransporter 2 inhibitor (SGLT2i) use and urine albumin–creatinine ratio (UACR) levels. Methods: Multi-database, observational, cross-sectional study, using data from two US databases (Optum Claims and Optum EHR). Three cohorts were included: finerenone initiators with prior CKD-T2D, finerenone initiators with prior CKD-T2D and concomitant SGLT2i use, finerenone initiators with prior CKD-T2D stratified according to UACR. Results: In total, 1015 patients were included, 353 from Optum Claims and 662 from Optum EHR. Mean age was 72.0 and 68.4 years in Optum claims and EHR, respectively. Median eGFR was 44 and 44 ml/min/1.73 m2; and median UACR was 132 (28–698)/365 (74–1185.4) mg/g, in Optum Claims and EHR, respectively. 70.5/70.4% were taking renin-angiotensin system inhibitors, 42.5/53.3% SGLT2i. Overall, 9.0/6.3% of patients had baseline UACR 300 mg/g. Conclusion: Current management of patients with CKD-T2D reflects use of finerenone independently from background therapies and clinical characteristics, suggesting implementation of therapeutic strategies based on different modes of action.

本数据集为发表在《比较疗效研究杂志》上的文章《美国使用芬列尼酮的慢性肾脏病和2型糖尿病患者特征：一项多数据库横断面研究》的同行评审补充材料。补充队列定义（JSON）、补充概念集表达。目标：芬列尼酮对于治疗慢性肾脏病（CKD）和2型糖尿病（T2D）的患者既安全又有效。关于芬列尼酮在临床实践中的使用证据不足。研究目的：描述美国早期采用芬列尼酮患者的流行病学和临床特征，根据钠-葡萄糖共转运蛋白2抑制剂（SGLT2i）的使用情况和尿白蛋白-肌酐比值（UACR）水平进行描述。研究方法：采用来自两个美国数据库（Optum索赔数据库和Optum电子健康记录数据库）的多数据库、观察性、横断面研究。包括三个队列：既往有CKD-T2D病史的芬列尼酮起始使用者、既往有CKD-T2D病史且同时使用SGLT2i的芬列尼酮起始使用者、根据UACR水平分层既往有CKD-T2D病史的芬列尼酮起始使用者。研究结果：总计包括1015名患者，其中Optum索赔数据库中353人，Optum电子健康记录数据库中662人。Optum索赔数据库和电子健康记录数据库的平均年龄分别为72.0岁和68.4岁。eGFR的中位数为44和44 ml/min/1.73 m2；UACR的中位数为132（28–698）/365（74–1185.4）mg/g，分别在Optum索赔数据库和电子健康记录数据库中。70.5/70.4%的患者正在服用肾素-血管紧张素系统抑制剂，42.5/53.3%的患者使用SGLT2i。总体而言，9.0/6.3%的患者基线UACR为300 mg/g。研究结论：目前对CKD-T2D患者的管理反映了在背景治疗和临床特征之外独立使用芬列尼酮，这表明应实施基于不同作用机制的药物治疗策略。